# Atlas Interoperability Readiness Demo

## Buyer Brief
- Product: SCRIMED Atlas
- Buyer: CIOs, integration leaders, security teams, and healthcare platform owners
- Agent: Interoperability Agent
- Status: executable-demo
- Executable route: /interoperability/evaluations

## Objective
Demonstrate standards-aware synthetic conformance evidence with exact live-use blockers retained.

## Synthetic Scenario
FHIR R4 and US Core, SMART App Launch, and DICOMweb test kits run deterministic checks against synthetic fixtures and connector contracts.

## Guided Evaluation
- Inspect aggregate synthetic conformance status.
- Open a standards-specific evaluation kit.
- Review passed deterministic checks and linked evidence.
- Confirm certification, partner acceptance, and live exchange remain blocked.

## Inspectable Proof
- [FHIR R4 and US Core kit](/interoperability/evaluations/fhir-r4-us-core-intake): Synthetic profile checks and deployment-specific live blockers.
- [SMART App Launch kit](/interoperability/evaluations/smart-app-launch-authorization): Synthetic launch controls with identity and authorization blockers.
- [DICOMweb kit](/interoperability/evaluations/dicomweb-imaging-exchange): Synthetic imaging exchange checks and partner acceptance blockers.

## Inspectable Outcomes
- Standards target registry
- Deterministic conformance results
- Evidence artifact links
- Exact live-use blocker list

## Success Signals
- Interoperability gaps surfaced
- Standards ownership clarified
- Pre-live requirements made inspectable
- Connector claims kept truthful

## Governance Boundaries
- Synthetic connector evidence only.
- Every standards kit retains deployment-specific blockers.
- Partner testing and production acceptance remain separate gates.

## Production Exclusions
- No live healthcare data exchange
- No connector certification claim
- No trading-partner acceptance claim
- No production record mutation

## Product Boundary
SCRIMED demos and pilot programs are governed synthetic evaluations for enterprise buyers. They do not ingest live PHI, diagnose, treat, submit payer transactions, contact patients, mutate production records, or autonomously execute clinical care.

This brief supports enterprise evaluation and pilot scoping. It is not clinical advice, a production authorization, a certification claim, or evidence of autonomous clinical execution.